The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to a therapeutic combination which comprises a PD-1 axis binding antagonist, a TGFβ inhibitor and a DNA-PK inhibitor, optionally together with one or more additional chemotherapeutic agents or radiotherapy. The therapeutic combination is particularly intended for use in treating a subject having a cancer that tests positive for PD-L1 expression.本發明係關於適用於治療癌症之組合治療。特別地，本發明係關於包含PD-1軸結合拮抗劑、TGFβ抑制劑及DNA-PK抑制劑，視需要與一或多種另外之化學治療劑或放射治療一起之治療組合。該治療組合尤其旨在用於治療患有測試PD-L1表現呈陽性之癌症之個體。
